MAP kinase kinase 1 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “MAP kinase kinase 1 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in MAP kinase kinase 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
MAP kinase kinase 1 inhibitors: Overview
MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as they lie downstream of important drug targets for oncology, such as EGFR, RAS and RAF. MEK inhibitors hold promise for use as combination therapies for highly prevalent, genetically defined cancers owing to the critical role that the MAPK pathway plays in the growth and proliferation of many cancer types (including lung cancer, melanoma, pancreatic cancer, colorectal cancer, endometrial cancer, and ovarian cancer).
Report Highlights
This segment of the MAP kinase kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MAP kinase kinase 1 inhibitors Emerging Drugs
Further product details are provided in the report……..
MAP kinase kinase 1 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different MAP kinase kinase 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
MAP kinase kinase 1 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MAP kinase kinase 1 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MAP kinase kinase 1 inhibitors drugs.
MAP kinase kinase 1 inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “MAP kinase kinase 1 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in MAP kinase kinase 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
MAP kinase kinase 1 inhibitors: Overview
MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as they lie downstream of important drug targets for oncology, such as EGFR, RAS and RAF. MEK inhibitors hold promise for use as combination therapies for highly prevalent, genetically defined cancers owing to the critical role that the MAPK pathway plays in the growth and proliferation of many cancer types (including lung cancer, melanoma, pancreatic cancer, colorectal cancer, endometrial cancer, and ovarian cancer).
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence MAP kinase kinase 1 inhibitors R&D. The therapies under development are focused on novel approaches for MAP kinase kinase 1 inhibitors.
This segment of the MAP kinase kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MAP kinase kinase 1 inhibitors Emerging Drugs
- Selumetinib: AstraZeneca
- Mirdametinib: SpringWorks Therapeutics
Further product details are provided in the report……..
MAP kinase kinase 1 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different MAP kinase kinase 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on MAP kinase kinase 1 inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
MAP kinase kinase 1 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MAP kinase kinase 1 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MAP kinase kinase 1 inhibitors drugs.
MAP kinase kinase 1 inhibitors Report Insights
- MAP kinase kinase 1 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing MAP kinase kinase 1 inhibitors drugs?
- How many MAP kinase kinase 1 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of MAP kinase kinase 1 inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the MAP kinase kinase 1 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for MAP kinase kinase 1 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- SpringWorks Therapeutics
- Array BioPharma
- Novartis
- Chongqing Fochon Pharmaceutical
- Recursion Pharmaceuticals
- CStone Pharmaceuticals
- Selumetinib
- Mirdametinib
- Binimetinib
- Trametinib
- FCN 159
- REC 4881
- CS 3006
Introduction
Executive Summary
MAP kinase kinase 1 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
MAP kinase kinase 1 inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Selumetinib: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Mirdametinib: SpringWorks Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
CS 3006: CStone Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
REC 4881: Recursion Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
MAP kinase kinase 1 inhibitors Key Companies
MAP kinase kinase 1 inhibitors Key Products
MAP kinase kinase 1 inhibitors- Unmet Needs
MAP kinase kinase 1 inhibitors- Market Drivers and Barriers
MAP kinase kinase 1 inhibitors- Future Perspectives and Conclusion
MAP kinase kinase 1 inhibitors Analyst Views
MAP kinase kinase 1 inhibitors Key Companies
Appendix
Executive Summary
MAP kinase kinase 1 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
MAP kinase kinase 1 inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Selumetinib: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Mirdametinib: SpringWorks Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
CS 3006: CStone Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
REC 4881: Recursion Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
MAP kinase kinase 1 inhibitors Key Companies
MAP kinase kinase 1 inhibitors Key Products
MAP kinase kinase 1 inhibitors- Unmet Needs
MAP kinase kinase 1 inhibitors- Market Drivers and Barriers
MAP kinase kinase 1 inhibitors- Future Perspectives and Conclusion
MAP kinase kinase 1 inhibitors Analyst Views
MAP kinase kinase 1 inhibitors Key Companies
Appendix